We use cookies for a better user experience. Read our Privacy Policy

I Agree

Psychedelic Drugs Market

Psychedelic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Psychedelic Drugs Market: Evolution Contours

Interest in psychedelic medicine has reemerged in psychiatry after a brief period of prohibition of the use of psychedelic substances—from 1950s to the early 1970. Unrefutably, psychedelics or serotonergic hallucinogens show promising potential to treat mood disorders and alcohol dependence. Especially lysergic acid diethylamide (LSD) drug has shown significant safety and tolerability in end-of-life psychological distress.

The prohibitive legislatures and discontinuation of research stemmed mainly from the widespread negative public perception of the harms caused due to their illicit use on one hand. The social stigma related to the recreational use of select psychedelics and the ethical conundrum relating to the restricted use have had debilitating impact on clinical trials.

Before the ban, various psychedelics of plant extraction had attracted groundswell of attention in Europe and North America. Interestingly, a number of multicenter studies notably supported by the U.S. FDA and European Medicines Agency (EMA) have reinvigorated research in exploring the therapeutic potential of classical psychedelic drugs, opening a new paradigm in the psychedelic drugs market.

Psychedelic Drugs Market: Drivers, Current Prospects, and Emerging Avenues

Since the early 1990s, continued clinical trials have unraveled the trials in psychedelic drugs market open up several areas of applications in the medical industry. The trend in psychedelic drugs market development is led by the emerging paradigm of psychedelic psychotherapy gaining acceptance in heterogeneous health systems. Preliminary data supported by modern meta-analysis found LSD and 3,4-methylene dioxymethamphetamine (MDMA) in psychiatric research for treatment of alcoholism and post-traumatic stress disorder (PTSD), respectively. Expanding knowledge of pharmacology of psychedelics and the increasing adoption of modern-day medical imaging tools in psychopharmacological experiments broadening horizon of the psychedelic drugs market.

The unmet need of sufficient double-blinded studies in psilocybin research is a vast avenue for companies in the healthcare and medical sectors in psychedelic drugs market to find new commercialization prospect for psychedelic therapy in psychiatry. Another significant trend is technological advancements made in human neuroimaging. Focus on controlled, clinical use of psychedelics in medicine, where clinician–patient relationship is equally important as psychological expectations and the medical setting, will stridently spur positive outcomes from research on psychedelic agents.

Psychedelic Drugs Market: Competitive Scenario

Since early years of the millennium, R&D in the psychedelic drugs market has largely been small-scale pilot studies. In recent times, pioneers in psychedelics-assisted psychotherapy are growing their investment in randomized controlled trials to establish the clinical utility of drugs in the pipeline. In developed nations, government grants have supported such initiatives. Top players are leaning on better methodological designs and complying with current clinical protocols. Additionally, biopharmaceutical companies are giving more caution on ethical strictures that are region-specific in order to attract a large number of participants for their clinical trials. Of note, researchers are also emphasizing on standardization to be used in monitoring participants in randomized clinical trials. All this will pave way for lucrative revenue prospects in the psychedelic drugs market. Furthermore, the use of psychedelics in controlled settings with medical supervision will likely boost the arena of psychedelic medicine in guiding pharmacotherapeutic and ancillary psychotherapeutic choices.

Some of the key players in the psychedelic drugs market are Celon Pharma S.A., NeuroRx, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., and Hikma Pharmaceuticals PLC.

Psychedelic Drugs Market: Regional Avenues

Europe and North America have been lucrative psychedelic drugs markets. The immense revenue-generation possibilities stem from the recent positive outlook of policymakers in embracing and supporting new approaches to research in the therapeutic value of psychedelic drugs. The U.S. has proved to be replete with opportunities for market players. The need for extensive R&D in exploring novel treatments for substance use disorders and finding innovative treatment possibilities for Treatment-resistant patients in severe mental disorders in European countries have paved way to investments in the Europe psychedelic drugs market.

Psychedelic Drugs Market

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes


Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.


Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved